PURPOSE: To assess the effect of a bimonthly treatment regimen with intravitreal aflibercept on retinal fluid and @entity1713 ( @entity1713 ) in @entity1 with neovascular @entity1020 ( @entity1020 ). METHODS: Twenty-six treatment-naive eyes of 26 @entity1 with @entity3193 secondary to @entity1020 were included. The @entity1 received three initial monthly (mean 30 days) intravitreal injections of aflibercept followed by a bimonthly (mean 62 days) fixed regimen for a total of 1 year. Best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) measurements were recorded at monthly intervals. In addition, the presence of intraretinal fluid (IRF) or subretinal fluid (SRF) or a combination of both as well as serous and fibrovascular PEDs were assessed. RESULTS: The mean @entity1 age was 80 years (range 54-93). There were 14 male and 12 female @entity1 . The mean gain in BCVA at 1 year was 9.3 letters (SEM   3) with a mean reduction of the central retinal thickness of 154   m (SEM   50). After 3 monthly injections of aflibercept, there was resolution of IRF and SRF in 80% of the treated eyes; the amount of fluid increased at months 4, 6 and 8 with troughs in between. Whereas fibrovascular PEDs remained stable after the loading phase, serous PEDs displayed a seesaw pattern. @entity1 without @entity989 ( @entity989 ) @entity194 at the end of the 1-year period had significantly better BCVA compared to @entity1 with @entity989 @entity194 (p = 0.03). CONCLUSION: Despite significant overall BCVA gain, bimonthly intervals seem insufficient to maintain the morphological improvements after the initial loading dose with intravitreal aflibercept.

Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['pigment epithelial detachment', 'PED'] @entity3193 :: ('MESH:D015862', 'Disease') :: ['choroidal neovascularisation'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinal pigment epithelium', 'RPE'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD', 'age-related macular degeneration']
@entity1020 :: (MESH:D008268,Disease) :: ['Macular Degeneration']
